During a median duration of 2.5 years , the primary end point occurred in 903 patients in the darapladib group and 910 in the placebo group ( 16.3 % vs 15.6 % at 3 years ; hazard ratio [ HR ] , 1.00 [ 95 % CI , 0.91-1 .09 ] ; P = .93 ) .
